iData Insights

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024 Now Available at iData Insights

News   •   Jan 02, 2016 13:03 IST

consists of the brain and spinal cord, including the brain stem (NCI, 2015). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumors, (ABTA, 2014). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth, and only those tumors that are malignant are designated as cancer (NCI, 2015). Primary brain tumors are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumors are those that start elsewhere in the body and migrate to the brain or other parts of the CNS. In the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate (AGR) of 1.30%. The US will have the highest number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The five-year diagnosed prevalent cases of brain cancer are also expected to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of 0.62%. The US will have the highest number of five-year diagnosed prevalent cases of brain cancer in 2014 and 2024, at 42,104 cases and 46,401 cases, respectively. This report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumors originating in the CNS (ICD-10 codes C70-C72). Scope - The brain cancer EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). This report includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). - The brain cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists. - The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. Reasons to buy The brain cancer EpiCast report will allow you to - - Develop business strategies by understanding the trends shaping and driving the global brain cancer market. - Quantify patient populations in the global brain cancer market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.

Browse Complete Report with TOC @http://www.idatainsights.com/reports-landing-page.php?id=161208/epicast-report-brain-cancer-epidemiology-forecast-to-2024

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=161208/epicast-report-brain-cancer-epidemiology-forecast-to-2024

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Catalyst 7

2.2 Related Reports 7

2.3 Upcoming Reports 8

3 Epidemiology 9

3.1 Disease Background 9

3.2 Risk Factors and Comorbidities 10

3.3 Global Trends 11

3.3.1 7MM Incidence Trends 11

3.3.2 7MM Trends in Relative Survival 13

3.4 Forecast Methodology 14

3.4.1 Sources Used 14

3.4.2 Sources Not Used 18

3.4.3 Forecast Assumptions and Methods 19

3.5 Epidemiological Forecast for Brain Cancer (2014-2024) 21

3.5.1 Diagnosed Incident Cases of Brain Cancer 21

3.5.2 Age-Specific Diagnosed Incidence of Brain Cancer 23

3.5.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer 25

3.5.4 Age-Standardized Diagnosed Incidence of Brain Cancer 27

3.5.5 Five-Year Diagnosed Prevalent Cases of Brain Cancer 28

3.5.6 Diagnosed Incident Cases of Brain Cancer by Type 30

3.6 Discussion 31

3.6.1 Epidemiological Forecast Insight 31

3.6.2 Limitations of the Analysis 32

3.6.3 Strengths of the Analysis 33

4 Appendix 34

4.1 Bibliography 34

4.2 About the Authors 37

4.2.1 Epidemiologists 37

4.2.2 Reviewers 37

4.2.3 Global Director of Therapy Analysis and Epidemiology 39

4.2.4 Global Head of Healthcare 39

4.3 About GlobalData 40

4.4 About EpiCast 40

4.5 Disclaimer 41

4.6 Disclaimer 72

Read More http://www.idatainsights.com/reports-landing-page.php?id=161208/epicast-report-brain-cancer-epidemiology-forecast-to-2024

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects